Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 6Drug-Related Side Effects and Adverse Reactions 2Colorectal Neoplasms 2Advanced Gastric Cancer 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Quality of Life 1Peritoneal Metastases From Gastric Cancer 1Ovarian Cancer Recurrent 1Osteosarcoma 1Meningioma 1Immune Checkpoint Inhibition 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Chondrosarcoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Gastric Adenocarcinoma 1

Interventions

camrelizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Immune Checkpoint Inhibition × apatinib × Clear all
NCT04507750 2020-09-21

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Qianfoshan Hospital

Phase NA Unknown
40 enrolled

Immune Checkpoint Inhibition

Data powered by HemOnc (CC BY 4.0) Colophon âš¡